An interventional study of nasal cannula in Apnea, sponsored by Yasser S Mostafa, MD. Completed at 1 site in Egypt. Open to participants aged 1 Year to 6 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Yasser S Mostafa, MD · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background: Children desaturate rapidly during apnea following anesthetic induction. The optimal apneic oxygenation flow rate and its effect on CO2 accumulation remain unclear.
Objective: To compare nasal oxygen at 2, 4, and 8 L/min on the rise in arterial partial pressure of CO2 (PaCO2) between minutes 2 and 3 of apnea (primary outcome), oxygenation, and safety in anesthetized children.
Introduction Patients undergoing general anesthesia with neuromuscular blockade experience a period of apnea between cessation of mask ventilation and initiation of mechanical ventilation. This interval is particularly critical in infants and toddlers, who are prone to rapid desaturation because of higher oxygen consumption and lower functional residual capacity than older children and adults [1]. Accordingly, hypoxemia during induction and airway manipulation is associated with an increased incidence of postoperative complications and serious adverse events, including death [2,3].
Apneic oxygenation refers to the continuous insufflation of oxygen into the airway during apnea [4]. Several studies have shown that this approach effectively maintains oxygenation and reduces the risk of hypoxemia during tracheal intubation [5,6]. An ongoing challenge in pediatric anesthesia is to ensure adequate oxygenation while limiting lung volume loss and carbon dioxide accumulation during apnea, particularly during airway manipulation. Therefore, techniques that extend the duration of safe apnea without introducing additional risks are of considerable clinical relevance [7]. Accordingly, apneic oxygenation has gained attention as an adjunctive technique, with similar benefits reported in children using both low-flow and high-flow nasal oxygen, although pediatric data remain more limited [8].
Multiple studies have examined low-flow apneic oxygenation in children, showing that it reduces the incidence of hypoxemia and extends the duration of safe apnea, in some reports by up to several minutes, compared with no apneic oxygenation. Comparative data on CO2 kinetics across different low-flow rates in children are limited [9-11]. Therefore, this study aimed to examine the effect of different flow oxygen rates applied during a standardized 6-minute period of apnea on the increase in arterial partial pressure of CO2 (PaCO2) in anesthetized, paralyzed children.
Sample size No previous data were available for the primary outcome, the rise in PaCO₂ between the 2nd and 3rd minutes of apnea (ΔPaCO₂, mmHg), so a pilot study of five children per group was performed. These pilot children were a separate, non-randomized cohort and were excluded from the modified intention-to-treat analysis. The mean ± SD ΔPaCO₂ was 4.2 ± 1.6, 3.4 ± 1.5 and 2.8 ± 1.4 mmHg at 2, 4 and 8 L/min. The largest difference (2 vs 8 L/min) was 1.4 mmHg, a one-third reduction, considered clinically meaningful as it would delay hypercapnia and respiratory acidosis during apnea; the pooled SD for these two groups was 1.5 mmHg (Cohen's d = 0.93). For three pairwise comparisons with 1:1:1 allocation, a two-sided alpha of 0.0167 (0.05/3) and 80% power, at least 26 children per group were required (independent-samples t-test, G*Power 3.1.9.7), used as an approximation for the three-group ANOVA design. Allowing for 15% loss of data, 30 children were enrolled per group (90 total).
283 studies on the registry are indexed under Apnea; 55 are open to participants now.
This study's enrollment of 90 is above the median of 60 across 196 interventional studies indexed under Apnea.
Browse Apnea studies →Yasser S Mostafa, MD is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low flow 100% O2 AT 2 L/min
Device: nasal cannula
Low flow 100% O2 AT 4 L/min
Device: nasal cannula
Low flow 100% O2 AT 8 L/min
Device: nasal cannula
After induction, bag-mask ventilation with 100% oxygen and flow rates of 6 L/ min will be carried out until the expired oxygen concentration will be \>90%, saturation of oxygen was 100%, and end tidal carbon dioxide was 30-40 mmHg. Once this will be reached, bag-mask ventilation will be stopped and apneic oxygenation will be initiated for 3 minutes
Also known as: oxygen nasal cannula
rise of arterial pressure of carbon dioxide
mmHg
Time frame: between 120s and 180s time points of apnea
Time to oxygen desaturation
below 95%
Time frame: 5 seconds after the onset of apnea
Number of patients reached 6 minutes of apnea
Count number of patients in each group
Time frame: 1 minute after end of apneic oxygenation
Pressure difference between the end-tidal carbon dioxide and the arterial carbon dioxide
mmHg
Time frame: Between the end of apnea and the preceding blood gas
Mean difference in arterial pressure of oxygen
mmHg
Time frame: at the beginning of apnea
Mean difference in arterial pressure of oxygen
mmHg
Time frame: at the end of apnea time
Lowest recorded oxygen saturation
in percentage (%)
Time frame: throughout the apneic oxygenation
Heart rate
beat/minute
Time frame: Before anaesthetizing child
Mean arterial blood pressure
mmHg
Time frame: Before anaesthetizing child
Heart rate
beat/minute
Time frame: During apnea time
Mean arterial blood pressure
mmHg
Time frame: During apnea time
Occurence of sore throat
Yes or no
Time frame: in first postoperative day
Age
Years
Time frame: 1 hour preoperatively
Weight
Kilogram
Time frame: 1 hour preoperatively
Plan to share: No
Ran from Nov 2024 to primary completion in May 2026, 18 months.
Of 69 non-industry interventional studies with no phase under Apnea, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 18 months is close to that.
Counting every sponsor, half of 78 studies reached it within 17 months; a quarter within 8 and three quarters within 35.
Start moved once since we started tracking on Sep 25, 2026: Oct 2024 → Nov 2024, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yasser S Mostafa, MD